Tom 3, Supl. A (2023)
Artykuł redakcyjny
Opublikowany online: 2023-03-23
Wyświetlenia strony
352
Wyświetlenia/pobrania artykułu
43
Ruksolitynib w leczeniu przewlekłej choroby przeszczep przeciwko gospodarzowi — nowy gracz w drużynie
1
Streszczenie
Brak
Referencje
- Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017; 377(26): 2565–2579.
- MacDonald KPA, Hill GR, Blazar BR. Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood. 2017; 129(1): 13–21.
- Fuji S, Byrne M, Nagler A, et al. How we can mitigate the side effects associated with systemic glucocorticoid after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021; 56(6): 1248–1256.
- Zeiser R, Polverelli N, Ram R, et al. REACH3 Investigators. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med. 2021; 385(3): 228–238.
- Ferreira AM, Szor RS, Molla VC, et al. Long-term follow-up of ruxolitinib in the treatment of steroid-refractory chronic graft-versus-host disease. Transplant Cell Ther. 2021; 27(9): 777.e1–777.e6.
- Wang D, Liu Y, Lai X, et al. Efficiency and toxicity of ruxolitinib as a salvage treatment for steroid-refractory chronic graft-versus-host disease. Front Immunol. 2021; 12: 673636.
- Fan S, Huo WX, Yang Y, et al. Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis. Front Immunol. 2022; 13: 954268.
- Greinix HT, Ayuk F, Zeiser R. Extracorporeal photopheresis in acute and chronic steroid‑refractory graft-versus-host disease: an evolving treatment landscape. Leukemia. 2022; 36(11): 2558–2566.
